がん幹細胞治療の世界市場

◆英語タイトル:Global Cancer Stem Cell Therapy Market Outlook 2020
◆商品コード:KUIK60808
◆発行会社(調査会社):KuicK Research
◆発行日:2016年4月
◆ページ数:132
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single userUSD2,400 ⇒換算¥266,400見積依頼/購入/質問フォーム
Multi UserUSD4,800 ⇒換算¥532,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規販売代理店です。KuicK Research社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Investigators discovered stem cells during their quest to find innovative cell therapy methods which could offer edge over prevailing modalities. These cells have ability to divide several times without losing their capability to renew again and again. This is very important because earlier, investigators believed that one type of cell is capable to giving rise to another kind of cell which means they can’t change. But their discovery changed the whole scenario as a result of which several degenerative diseases could be treated. Before doing so it is imperative to classify; study and recognize their differentiation potential in clinical settings. Different types of stem cells are available due to which investigators have more choices to customize their clinical development. Their utility in cancer treatment has been noted by investigators and they have also found that it could also be used for organ repair.
Recombinant technology has improved significantly in past years due to which better therapeutics are expected to be developed in coming years. Many cancer drugs have been developed by utilization of these techniques. Cancer stem cell therapies are also expected to be developed with its help. They are expected to have superior therapeutic effects as compared to conventional therapeutics. With time, mass production is also expected to improve with improve in technology. Higher production at lower cost will allow the pharmaceutical companies to gain more market shares. They will be able to commercialize highly effective cancer stem cell therapeutics at lesser prices. In this way, they will be able to effectively compete in already overcrowded cancer therapeutics segment across the globe.
Utilization of cancer stem cells is expected to play an important role in treatment of various cancers like breast and lung cancer. Other cancers like pancreatic cancer, gastric cancer and other cancers which have been studied to lesser extent are going to have significant boost. For this, they have to identify unique features related to different cancers. Investigators are developing biochips which are expected to identify different kind of cancers. Development of this technology requires significant investments along with development of associated technology. It will allow the investigators to generate result with high confidence levels. Some time is expected to be consumed during development of these biochips.

Investigators are looking for biomolecules with therapeutic efficacy that could be used in case of cancer stem cells. Micro RNA has been identified as potential candidate which can effectively counteract the cancer stem cells. Such inhibitors are expected to have high specificity due to which lesser side effects are expected to be developed. Many properties of micro RNAs has yet to be deciphered because their side effects are not known. Concerns related to their effect on normal genes have been raised by several researchers that may hamper normal cellular activities. Most of the work has been done at laboratory levels due to which lots of time is expected to be consumed in their commercialization. Cost of these therapeutics is also a major concern as they will be out of access of several cancer patients.

Development of targeted drugs is going to play an important role in development in counteracting cancer stem cell therapy. These drugs are expected to have high specificity due to which normal cells will be spared during treatment. They will prevent the cancerous cells to develop resistance so that they won’t become recalcitrant. It will also prevent the development of new cancerous cells in the body. By preventing metastasis, spread of cancer cells in different body parts would be checked. Investigators are developing drug discovery systems which would be able to find new lead molecules for developing cancer stem cell therapies. Only few candidate molecules are able to effectively eliminate cancer stem cells. As a result, significant time is consumed in the development of cancer stem cell therapies.

“Global Cancer Stem Cell Therapy Market Outlook 2020” Report Highlight:
• Introduction & Classification of Stem Cells
• Stem Cell Transplants Classification
• Cancer Stem Cell Therapy Mechanism of Action
• Global Cancer Stem Cell Market Analysis
• Global Cancer Stem Cell Clinical Pipeline by Company & Phase
• Global Cancer Stem Cell Clinical Pipeline: 32 Therapies
• Global Cancer Stem Cell Market Dynamics: Challenges & Favorable Parameters
• Global Cancer Stem Cell Market Future Outlook

【レポートの目次】

1. Introduction to Stem Cells

2. Classification of Stem Cells
2.1 Basis of Ability to Differentiate
2.2 Basis of Origin
2.3 Basis of their Source

3. Stem Cell Transplants Classification
3.1 Autologous Stem Cell Transplants
3.2 Allogeneic Stem Cell Transplants
3.3 Syngeneic Stem Cell Transplants

4. Cancer Stem Cell Therapy Mechanism of Action
4.1 Targeting Signaling Pathways
4.1.1 Hedgehog Signaling Pathway
4.1.2 Notch Signaling Pathway
4.1.3 WNT Signaling Pathway
4.2 Targeting Cell Surface Markers
4.3 Targeting miRNA Expression

5. Global Cancer Stem Cell Market Analysis
5.1 Current Market Scenario
5.2 Global Cancer Stem Cell Therapies Pipeline Overview

6. Global Cancer Stem Cell Market Dynamics
6.1 Favorable Market Parameters
6.2 Commercialization Challenges

7. Global Cancer Stem Cell Market Future Outlook

8. Global Cancer Stem Cell Clinical Pipeline by Company & Phase
8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase-I
8.5 Phase-I/II
8.6 Phase-II
8.7 Phase-III

9. Discontinued & No Development of Cancer Stem Cell in Clinical Pipeline by Company & Phase
9.1 Discontinued
9.2 No Development Reported

10. Competitive Landscape
10.1 Aldagen
10.2 Apceth
10.3 Benitec Biopharma
10.4 Celgene Corporation
10.5 Cellonis Biotechnologies
10.6 Caladrius Biosciences
10.7 Commence Bio
10.8 ExCellThera
10.9 Galena Biopharma
10.10 Gamida Cell
10.11 Genexine
10.12 ImmunoCellular Therapeutics
10.13 K-STEMCELL
10.14 Medipost
10.15 Mesoblast
10.16 Novartis
10.17 Nuo Therapeutics
10.18 OncoCyte Corporation
10.19 Pluristem Therapeutics
10.20 ReNeuron
10.21 Sangamo BioSciences
10.22 Takeda
10.23 Vericel Corporation

Figure 1-1: Properties of Stem Cells
Figure 1-2: Utility of Stem Cells
Figure 1-3: Benefits of Stem Cells
Figure 1-4: Limitations of Stem Cells
Figure 2-1: Type of Stem Cells on the Basis of Ability to Differentiate
Figure 2-2: Type of Stem Cells on the Basis of Origin
Figure 2-3: Types of Stem Cells on the Basis of their Source
Figure 2-4: Different Sources of Autologous Stem Cell
Figure 3-1: Different Stem Cell Transplants
Figure 4-1: Development of Resistance in Cancerous Cells against Therapeutics
Figure 4-2: Approach for Developing Cancer Stem Cells based Therapies
Figure 4-3: Targeting Different Signaling Pathways
Figure 4-4: Mechanism of Hedgehog Signaling Pathway
Figure 4-5: Mechanism of Notch Signaling Pathway
Figure 4-6: Mechanism of Wnt Signaling Pathway
Figure 4-7: Mechanism of Cell Surface Marker for Cancer Treatment
Figure 4-8: Mechanism of miRNA Targeting
Figure 5-1: Difference between Autologous & Autogenic HSCTs
Figure 5-2: Global Stem Cell Market Opportunity (US$ Billion), 2015-2020
Figure 5-3: Global Cancer Stem Cell Therapies Pipeline by Phase (%), 2016
Figure 5-4: Global Cancer Stem Cell Therapies Pipeline by Phase (Numbers), 2016
Figure 5-5: Global Cancer Stem Cell Therapies Pipeline by Phase (%), 2016
Figure 5-6: Global Cancer Stem Cell Therapies Pipeline by Phase (Numbers), 2016
Figure 6-1: Global Cancer Stem Cell Market Favorable Parameters
Figure 6-2: Global Cancer Stem Cell Market Commercialization Challenges
Figure 10-1: Benitec - Biopharma Clinical Pipeline
Figure 10-2: Celgene- Clinical Pipeline
Figure 10-3: Caladrius - Clinical Pipeline
Figure 10-4: Commence Bio - Clinical Pipeline
Figure 10-5: Galena Biopharma - Clinical Pipeline
Figure 10-6: Gamida Cell - Clinical Pipeline
Figure 10-7: Genexie - Clinical Pipeline
Figure 10-8: ImmunoCellular Therapeutics - Clinical Pipeline
Figure 10-9: Mesoblast - Clinical Pipeline
Figure 10-10: OncoCyte Corporation - Clinical Pipeline
Figure 10-11: ReNeuron - Clinical Pipeline
Figure 10-12: Sangamo BioSciences - Clinical Pipline
Figure 10-13: Takeda - Clinical Pipeline
Figure 10-14: Vericel – Clinical Pipeline


Table 2-1: Difference between Embryonic, Adult & Induced Stem Cells
Table 3-1: Comparison between Different Types of Stem Cell Transplants
Table 3-2: Few Autologous Stem Cell Therapies under Development


【レポートのキーワード】

幹細胞治療、がん治療

★調査レポート[がん幹細胞治療の世界市場]販売に関する免責事項
★調査レポート[がん幹細胞治療の世界市場]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆